Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclidinium Bromide 400 μg in Moderate to Severe COPD
NCT01636401Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aclidinium in chronic obstructive pulmonary disease (COPD), sponsored by Daewoong Pharmaceutical. Started Aug 2012; status: completed.
02
Drugs
aclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01636401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636401.